BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines accrued External R&D Activities Liability ($M) ($M)
Form 10-Q / 10-K Accrued Liabilities Note (XBRL)
Latest, Q2 2026
167
Period ended Jun 30, 2026
Change on a year earlier
+57.3%
106 in Q2 2025
History
37 quarters
Since Q4 2015
Sources
36
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accrued External R&D Activities Liability ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 167 | +57.3% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 199 | +117.7% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 157 | +1.4% | Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 125 | +11.6% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 106 | -20.4% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 91.6 | -7.5% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 154 | -5.3% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 112 | +20.9% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 133 | +46.4% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 99 | -30.8% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 163 | +17.1% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 92.7 | -18.7% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 91.1 | -39.8% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 143 | +26.9% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 139 | -34.9% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2022 | Sep 30, 2022 | 114 | -30.4% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 151 | -10.9% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 113 | -10.6% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2021 | Dec 31, 2021 | 214 | +49.3% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 164 | +17.1% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 170 | +70.8% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 126 | +136.3% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 143 | +128.2% | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2020 | Sep 30, 2020 | 140 | +124.7% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 99.4 | +112.8% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 53.4 | +13.9% | Form 10-Q (filed 2020-05-11) ↗ |
| Q4 2019 | Dec 31, 2019 | 62.8 | +81.5% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 62.3 | +84.9% | Form 10-Q (filed 2019-11-12) ↗ |
| Q2 2019 | Jun 30, 2019 | 46.7 | +12.3% | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 46.9 | +74.3% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 34.6 | +85.0% | Form 10-K (filed 2020-03-02) ↗ |
| Q3 2018 | Sep 30, 2018 | 33.7 | – | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jun 30, 2018 | 41.6 | – | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 26.9 | – | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 18.7 | +31.7% | Form 10-K (filed 2019-02-28) ↗ |
| Q4 2016 | Dec 31, 2016 | 14.2 | +246.3% | Form 10-K (filed 2018-02-28) ↗ |
| Q4 2015 | Dec 31, 2015 | 4.10 | – | Form 10-K (filed 2017-03-22) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Accrued External R&D Activities Liability ($M) ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/accrued_ext_rd
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.